Neocarzinostatinを中心とする多剤併用療法による急性白血病の再寛解導入

概要

論文の詳細を見る
Forty-two adults with acute leukemia in relapse were treated with Neocarzinostatin in combination with other antileukemic agents.Complete remissions (CR) were obtained in 17 of 42 cases (40.5%) in total. The CR rate was higher in the first relapse than in the second, in lymphatic than in non-lymphatic and in the group of ages under 50-year-old than over 50-year-old.The side effects other than myelosuppression were alopecia, gastrointestinal symptoms and abnormal liver function tests. The degree of these toxic effects was not so severe as to prevent clinical usage of combined antileukemic agents with Neocarzinostatin.The CR rate in the first induction was better than that in the reinduction. The comparative studies between the first induction and the reinduction were performed using the in vitro incorporation of labeled thymidine in leukemic cells before therapy and also the hematological changes before and after therapy. A higher rate of its incorporation was observed in the reinduction than in the first induction. And the number of leukocytes and nucleated cells in the bone marrow was much decreased in the reinduction than in the first induction, although the recovery of leukocytes and thrombocytes was much delayed in the first induction than in the reinduction. Consequently the time interval reaching CR became more delayed in the first induction than in the reinduction.
一般社団法人日本血液学会の論文